Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.88
- Piotroski Score 3.00
- Grade Overweight
- Symbol (AKYA)
- Company Akoya Biosciences, Inc.
- Price $3.17
- Changes Percentage (-1.71%)
- Change -$0.06
- Day Low $3.11
- Day High $3.24
- Year High $6.31
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $17.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.42
- Trailing P/E Ratio -1.44
- Forward P/E Ratio -1.44
- P/E Growth -1.44
- Net Income $-63,323,000
Income Statement
Quarterly
Annual
Latest News of AKYA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
PT Bank Rakyat Indonesia (Persero) Tbk (BKRKF) Q3 2024 Earnings Call Highlights: Strong Profit ...
Potential for lower credit costs in 2025 if current trends continue, with focus on improving asset quality vintages, capability-building programs for loan officers, and enhancing scoring and underwrit...
By Yahoo! Finance | 1 week ago -
While institutions own 21% of Akoya Biosciences, Inc. (NASDAQ:AKYA), private equity firms are its largest shareholders with 49% ownership
Three investors collectively own 52% of Akoya Biosciences, with private equity firms holding the largest stake at 49%. Institutions and hedge funds also have ownership, influencing the company's direc...
By Yahoo! Finance | 3 months ago
